Nkarta, Inc.
NKTX · XNASCIK 1787400fmd_0JRA0AYFJBY1TWKTETPD2ZM3ERManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | – | – | 0 | 0 |
| Research and development | 17 | 36 | 63 | 91 | 97 | 97 | 90 |
| Total operating expenses | 22 | 52 | 86 | 119 | 132 | 128 | 122 |
| Operating income | (22) | (52) | (86) | (119) | (132) | (128) | (122) |
| Other non-operating income (expense) | 1 | (40) | 0 | 5 | 14 | 19 | 18 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (21) | (91) | (86) | (114) | (118) | (109) | (104) |